CalciMedica (CALC)
Develops CRAC-channel inhibitors for inflammatory and cardiopulmonary disease.
Something off on this page? Send us feedback.
Develops CRAC-channel inhibitors for inflammatory and cardiopulmonary disease, led by the clinical candidate Auxora. Operates as a single, pre-revenue development business, funding outsourced research and manufacturing through equity capital.
Develops CRAC-channel inhibitors for inflammatory and cardiopulmonary disease, with Auxora as the lead clinical candidate. The California-based operation also has CM5480 in IND-enabling development, while CARPO and KOURAGE are trials of Auxora rather than separate product lines.
Operates as a single research-and-development segment with no approved products or product revenue. Development and manufacturing rely heavily on outside vendors, and operations depend on equity capital rather than customer sales.
Progress depends on clinical evidence, regulatory authorization, trial enrollment, intellectual-property protection and the capacity of contract research, clinical-site and manufacturing partners. The public issuer emerged from a reverse merger and must meet Nasdaq listing and SEC reporting standards.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.6M · Total debt $0 · Total assets $19.5M · Shareholders' equity $5.5M
- Revenue
- $0
- Operating income
- −$4.0M
- Net income
- −$7.7M
No dividends on record.
| Institutions28 holders · as of Mar 31, 2026 | 3.22% | 219.6K shares | |
| Insiders10 holders · as of Jul 7, 2026 | 19.33% | 1.32M shares | |
| Strategic holders2 holders · as of Jul 10, 2026 | 17.42% | 1.19M shares | |
| Otherremainder | 60.03% | 4.10M shares |
6.83M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (6.83M in the company's Sep 3, 2026 report, 3.15M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alafi Capital Co LLCStrategic10 percent owner | 14.97% | 1.02M | Form 4filed Jul 10, 2026 ↗ |
Evgeny ZaytsevInsiderdirector | 6.19% | 422,703 | Form 4filed Jul 7, 2026 ↗ |
Robert N. WilsonInsiderdirector | 4.70% | 320,930 | Form 4filed Jun 29, 2026 ↗ |
Fred A. MiddletonInsiderdirector, 10 percent owner | 3.22% | 219,957 | Form 4filed Jun 29, 2026 ↗ |
Sanderling Venture Partners VI Co Investment Fund LPStrategic10 percent owner | 2.45% | 167,356 | Form 4filed Nov 5, 2024 ↗ |
| See all 25 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 25, 2026 | Fred A. Middleton | director, 10 percent owner: | +248,972 | $0.8033 |
| Sep 18, 2025 | Eric W. Roberts | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | +2,500 | $3.07 |
| Sep 15, 2025 | Eric W. Roberts | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | +3,400 | $2.68 |
| Sep 12, 2025 | Eric W. Roberts | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | +5,000 | $3.12 |
| Sep 9, 2025 | Eric W. Roberts | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | +2,343 | $3.15 |
- United Therapeutics
PAH standard-of-care rival with a deep prostacyclin franchise.
- Johnson & Johnson
PAH portfolio rival across endothelin and prostacyclin-pathway care.
- Merck
PAH disease-modifying rival centered on WINREVAIR.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CalciMedica | $2.10 | +1.20% | $6.6M | — | — | — | — |
| United Therapeutics | $492.02 | +0.01% | $20.88B | 17.6 | 18.9 | 6.6 | −1.9% |
| Johnson & Johnson | $275.01 | −0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 31.9 | 18.9 | 6.6 | +5.1% |